ACP 001

Drug Profile

ACP 001

Alternative Names: ACP 011; ACP-001; TransCon growth hormone; TransCon hGH; TransCon PEG growth hormone; TransCon PEG hGH; TransCon PEG somatropin

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ascendis Pharma
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 28 Mar 2018 Ascendis Pharma completes enrolment in the phase III heiGHt trial in Somatotropin deficiency (In children, Treatment-naive) in USA, Italy, Greece and Poland
  • 08 Jan 2018 Ascendis plans to complete enrolment in the phase III fliGHt trial in Somatotropin deficiency (In infants, In children, In adolescents) during the third quarter of 2018
  • 19 Dec 2017 Ascendis Pharma initiates enrolment in the phase III enliGHten trial for Somatotropin-deficiency (In adolescents, In children, In infants, In adults) in USA (SC) (NCT03344458)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top